Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F012 - Psoriasis and Atopic Dermatitis: Advances in Therapy and Comorbidities

Friday, February 16; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate recent data of comorbidities in psoriasis and atopic dermatitis.
  • Discuss emerging therapies for psoriasis and atopic dermatitis.

Description

Psoriasis and atopic dermatitis are common, immune-mediated chronic diseases that have emerging therapeutic options (topical, oral, biologic, biosimilar). We will discuss optimal labs before starting therapy and labs while patients are on systemic therapy. We will compare and contrast comorbidities of these two conditions.

Disclosures

  • Egeberg, Alexander, MD, PhD: Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H), Speaker/Faculty Education(H); Galderma Laboratories, L.P. – SP(H); Janssen-Cilag – SP(H); Novartis – SP(H); Pfizer Inc. – I(Grants/Research Funding), SP(H);
  • Koo, John Y. M., MD: AbbVie – SP(H); Celgene Corporation – SP(H); Eli Lilly and Company – C(Fees); Leo Pharma Inc. – SP(H); Novartis Pharmaceuticals Corp. – SP(H); Pfizer Inc. – C(Fees);
  • Silverberg, Jonathan I., MD, PhD, MPH: AbbVie – C(H), I(NC); AnaptysBio – C(H); Asana Biosciences, LLC – C(H); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Glenmark Generics Inc. – C(H); Kiniksa Pharmaceuticals, Ltd. – C(H), I(NC); Leo Pharma Inc – A(H); Leo Pharma Inc. – I(H); Medimmune – C(H); Menlo Therapeutics – A(H), I(NC); Pfizer Inc. – A(H), C(H); PuriCore, Inc. – C(H); Regeneron – C(H), I(NC), SP(H); Sanofi – C(Grants/Research Funding);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees); Demira – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Leo Pharma Inc. – C(Fees); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding);
  • Wu, Jashin J., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene – C(H), SP(H); Demira – C(H); Dr Reddy's Laboratory – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(H); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Promius Pharma, LLC – C(H); Regeneron – C(H); Sun Pharmaceutical Industries Ltd. – C(H), SP(H); UCB – C(H), SP(H); Valeant Pharmaceuticals North America LLC – C(H), SP(H);
Schedule
Friday, February 16
9:00 AM
Dr. Wu / Welcome and introduction
9:05 AM
Egeberg / Psoriasis: comorbidities
9:25 AM
Dr. Silverberg / Atopic dermatitis: comorbidities
9:45 AM
Dr. Koo / Psoriasis: oral therapy, topical therapy, and phototherapy
10:10 AM
Dr. Simpson / Atopic dermatitis: therapy
10:35 AM
Dr. Wu / Psoriasis: biologics
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 23C
  • CME Credits
    2.00
  • Type
    New
Directors/Co-Directors
  • Jashin J. Wu, MD, FAAD
Speakers
  • Alexander Egeberg, MD, PhD
  • Eric Lawrence Simpson, MD, FAAD
  • John Y. M. Koo, MD, FAAD
  • Jonathan I. Silverberg, MD, PhD, MPH, FAAD